The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Multicenter phase I/II trial of topotecan (T) and ifosfamide (I) combination as second-line therapy for pediatric solid cancer: Phase II results.
Hiroshi Kawamoto
No relevant relationships to disclose
Mari Saito Oba
No relevant relationships to disclose
Ako Hosono
No relevant relationships to disclose
Yuji Ishida
No relevant relationships to disclose
Takashi Taga
No relevant relationships to disclose
Yoshiyuki Kosaka
No relevant relationships to disclose
Jiro Inagaki
No relevant relationships to disclose
Hideo Mugishima
No relevant relationships to disclose
Yasuhiro Okamoto
No relevant relationships to disclose
Atsushi Ogawa
No relevant relationships to disclose